APA (7th ed.) Citation

Crusoe, E. D. Q., Higashi, F., Martinez, G., Bittencourt, R., Neto, J. V. P., Sousa, L., . . . Hungria, V. T. d. M. (2020, April). Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation. Hematology, Transfusion and Cell Therapy.

Chicago Style (17th ed.) Citation

Crusoe, Edvan De Queiroz, et al. "Superiority of the Triple Combination of Bortezomib, Cyclophosphamide and Dexamethasone Versus Cyclophosphamide, Thalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma, Eligible for Transplantation." Hematology, Transfusion and Cell Therapy Apr. 2020.

MLA (9th ed.) Citation

Crusoe, Edvan De Queiroz, et al. "Superiority of the Triple Combination of Bortezomib, Cyclophosphamide and Dexamethasone Versus Cyclophosphamide, Thalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma, Eligible for Transplantation." Hematology, Transfusion and Cell Therapy, Apr. 2020.